<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503267</url>
  </required_header>
  <id_info>
    <org_study_id>CARDIoG</org_study_id>
    <nct_id>NCT02503267</nct_id>
  </id_info>
  <brief_title>&quot;Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects&quot;</brief_title>
  <acronym>(CARDIoG)</acronym>
  <official_title>&quot;Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects&quot; (CARDIoG)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari Vall d'Hebron Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari Vall d'Hebron Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to investigate congenital disorders of glycosylation in
      congenital heart diseases without a clear molecular or genetic basis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital disorders of glycosylation (CDG) are a family of inherited disorders caused by
      defects in the synthesis of glycans, glycoproteins or other glycoconjugates. Congenital
      disorders of glycosylation (CDG) are a family of inherited disorders caused by defects in the
      synthesis of glycans, glycoproteins or other glycoconjugates. Glycosylation of proteins is
      crucial for a proper organ morphogenesis and for an appropriate coagulation system
      functioning. The neurological system is commonly affected in this type of disorders but cases
      of CDG with normal neurological development have been recently described. The group of
      Experimental Hematology and Clinic Oncology of the University of Murcia (Spain) recently
      described a rare disorder of glycosylation (ALG12-CDG) as the cause of antithrombin
      deficiency in a patient of 19 years with a history of repaired ventricular septal defect.

      On the other hand, population studies have shown an increased incidence of thromboembolic
      events in patients with congenital heart disease when compared to the general population. The
      identified genetic defects involved in the development of congenital heart diseases have
      variable or incomplete penetrance and in most cases the molecular basis is completely
      unknown.

      The investigators postulate that a CDG might be behind the development of some forms of
      congenital heart disease and contribute to the greater prevalence of thromboembolic events in
      this patient population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Disorders of glycosylation</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of antithrombin deficiency</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Genetical alteractions of disorders of glycosylation</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Association between disorders of glycosylation and thromboembolic events</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Congenital Heart Diseases</condition>
  <condition>Conotruncal Defects</condition>
  <condition>Congenital Disorder of Glycosylation</condition>
  <condition>Antithrombin III Deficiency</condition>
  <arm_group>
    <arm_group_label>patients with congenital heart disease</arm_group_label>
    <description>patients with congenital heart disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>none intervention</intervention_name>
    <arm_group_label>patients with congenital heart disease</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Through the blood sample we will:

        -  Identify Antitrombin III deficiency

        -  Evaluate the glycosylation degree of different glycoproteins

        -  Do a genetic analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        250-300 adult patients who are most likely to have a congenital disorder of glycosylation
        of proteins, such as ventricular and atrial septal defects and especially conotruncal
        defects
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult with a congenital heart disease with most probability to present a congenital
             disorder of glycosylation of proteins

        Exclusion Criteria:

          -  Denial of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Berta Miranda, MD</last_name>
    <phone>+34934894038</phone>
    <phone_ext>4038</phone_ext>
    <email>bmiranda@vhebron.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vall d'Hebron Hospital</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berta Miranda, MD</last_name>
      <phone>+34932743164</phone>
      <email>bmiranda@vhebron.net</email>
    </contact>
    <contact_backup>
      <last_name>Laura Dos, MD,PhD</last_name>
      <phone>+34932743164</phone>
      <email>ldos@vhebron.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Footitt EJ, Karimova A, Burch M, Yayeh T, Dupré T, Vuillaumier-Barrot S, Chantret I, Moore SE, Seta N, Grunewald S. Cardiomyopathy in the congenital disorders of glycosylation (CDG): a case of late presentation and literature review. J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S313-9. doi: 10.1007/s10545-009-1262-1. Epub 2009 Sep 7. Review.</citation>
    <PMID>19757145</PMID>
  </reference>
  <reference>
    <citation>Gehrmann J, Sohlbach K, Linnebank M, Böhles HJ, Buderus S, Kehl HG, Vogt J, Harms E, Marquardt T. Cardiomyopathy in congenital disorders of glycosylation. Cardiol Young. 2003 Aug;13(4):345-51. Review.</citation>
    <PMID>14694955</PMID>
  </reference>
  <reference>
    <citation>Romano S, Bajolle F, Valayannopoulos V, Lyonnet S, Colomb V, de Baracé C, Vouhe P, Pouard P, Vuillaumier-Barrot S, Dupré T, de Keyzer Y, Sidi D, Seta N, Bonnet D, de Lonlay P. Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG Ia). J Med Genet. 2009 Apr;46(4):287-8. doi: 10.1136/jmg.2008.057620.</citation>
    <PMID>19357119</PMID>
  </reference>
  <reference>
    <citation>Mitra N, Sinha S, Ramya TN, Surolia A. N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci. 2006 Mar;31(3):156-63. Epub 2006 Feb 10. Review. Erratum in: Trends Biochem Sci. 2006 May;31(5):251.</citation>
    <PMID>16473013</PMID>
  </reference>
  <reference>
    <citation>Lin YS, Liu PH, Wu LS, Chen YM, Chang CJ, Chu PH. Major adverse cardiovascular events in adult congenital heart disease: a population-based follow-up study from Taiwan. BMC Cardiovasc Disord. 2014 Mar 21;14:38. doi: 10.1186/1471-2261-14-38.</citation>
    <PMID>24655794</PMID>
  </reference>
  <reference>
    <citation>de la Morena-Barrio ME, Hernández-Caselles T, Corral J, García-López R, Martínez-Martínez I, Pérez-Dueñas B, Altisent C, Sevivas T, Kristensen SR, Guillén-Navarro E, Miñano A, Vicente V, Jaeken J, Lozano ML. GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet J Rare Dis. 2013 Oct 20;8:170. doi: 10.1186/1750-1172-8-170.</citation>
    <PMID>24139637</PMID>
  </reference>
  <reference>
    <citation>Martínez-Martínez I, Ordóñez A, Navarro-Fernández J, Pérez-Lara A, Gutiérrez-Gallego R, Giraldo R, Martínez C, Llop E, Vicente V, Corral J. Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation. Haematologica. 2010 Aug;95(8):1358-65. doi: 10.3324/haematol.2009.015487. Epub 2010 Apr 30.</citation>
    <PMID>20435622</PMID>
  </reference>
  <reference>
    <citation>Aguila S, Martínez-Martínez I, Dichiara G, Gutiérrez-Gallego R, Navarro-Fernández J, Vicente V, Corral J. Increased N-glycosylation efficiency by generation of an aromatic sequon on N135 of antithrombin. PLoS One. 2014 Dec 8;9(12):e114454. doi: 10.1371/journal.pone.0114454. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0122177.</citation>
    <PMID>25485983</PMID>
  </reference>
  <reference>
    <citation>Dorn C, Grunert M, Sperling SR. Application of high-throughput sequencing for studying genomic variations in congenital heart disease. Brief Funct Genomics. 2014 Jan;13(1):51-65. doi: 10.1093/bfgp/elt040. Epub 2013 Oct 3. Review.</citation>
    <PMID>24095982</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2015</study_first_submitted>
  <study_first_submitted_qc>July 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antithrombin III deficiency</keyword>
  <keyword>congenital heart diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Antithrombin III Deficiency</mesh_term>
    <mesh_term>Congenital Disorders of Glycosylation</mesh_term>
    <mesh_term>Heart Septal Defects</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

